Single-site Pilot Study Evaluating the Effect of QLS-111 Ophthalmic Solution on Posterior Perfusion and Vessel Dilation

Recruiting

Phase 2

QLS-111Single-site Pilot Study Evaluating the Effect of QLS-111 Ophthalmic Solution on Posterior Perfusion and Vessel Dilation

Sponsor:

Qlaris Bio, Inc.

Code:

NCT07354477

Conditions

Non-proliferative Diabetic Retinopathy (NPDR)

Open-angle Glaucoma (OAG)

Normal Tension Glaucoma (NTG)

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

QLS-111 Ophthalmic Solution (0.015%)

QLS-111 Ophthalmic Solution (0.075%)

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2026-06-28. This information was provided to ClinicalTrials.gov by Qlaris Bio, Inc. on 2026-02-24.